Cumberland Pharmaceuticals Posts 31% Q4 Revenue Growth to $13.7M and Cuts Credit
Cumberland Pharmaceuticals posted Q4 2025 revenue of $13.7 million, a 31% year-over-year increase, and full-year revenue of $44.5 million, up 18%, while narrowing its Q4 net loss to $1.4 million. The company reduced its line of credit by over $10 million and expanded approvals in China and Mexico.
1. Q4 and Full-Year Financial Performance
Cumberland Pharmaceuticals reported Q4 2025 revenue of $13.7 million, up 31% from a year earlier, and full-year revenue of $44.5 million, up 18%. The company narrowed its net loss to $1.4 million in Q4 and $2.9 million for the year, with adjusted earnings rising to $0.11 per share.
2. Global Expansion and Product Portfolio
The company secured regulatory approvals in China and Mexico and launched its flagship antibiotic and antiemetic in Saudi Arabia. It also added Telicia, an FDA-approved Helicobacter pylori treatment, broadening its gastrointestinal care offerings.
3. Pipeline Progress and R&D Milestones
Clinical pipeline advanced with breakthrough results in the F DMD study, leading to FDA fast track designation for its Duchenne muscular dystrophy program, bolstering its long-term growth prospects.
4. Balance Sheet and Financial Position
Operating expenses increased to $15 million in Q4, driven by higher royalties and cost of goods, while shareholder equity improved and the line of credit balance was reduced by over $10 million. Total liabilities stood at $52.3 million, including $5.2 million on its credit facility.